 next-day memori impair triazolam preval rate degre memori impair next-day activ short intermitt cours bedtim dose triazolam temazepam placebo double-blind parallel-group studi subject triazolam group episod next-day memori impairment/amnesia total episod subject-drug night rate temazepam group episod memori impair immedi recal activ drug placebo night impair delay recal sever time temazepam placebo group next-day memori impairment/amnesia bedtim dose triazolam continu intermitt drug use cognit impair triazolam spectrum organ brain dysfunct memori impairment/amnesia confus commonest milder manifest hallucin delus sever common featur